… A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer. Clinical …

… Our recent study reported on the combination of Celecoxib … finding indicated an additive
mechanism of Celecoxib and … Citation2014), however, to the best of our knowledge, this is the …

… of erlotinib combined celecoxib (EC) for the treatment of advanced non-small cell lung cancer
(ANSCLC), no study … [27] Another study established the optimal biological dose (OBD), and …

… study aimed to identify the radiosensitizing effect of celecoxib… combination with radiotherapy
in non-small-cell lung cancer (… Gy/min for 1 min; The maximum dosage of 6 Gy was selected …

… From this biological rationale, although more toxic, the combination … The erlotinib–celecoxib
combination also increases radiation … In addition, it is necessary to determine the best way to …

… The anti-cancer role of celecoxib is through various intrinsic … A phase I clinical trial showed
that a combination of erlotinib … dose-limiting toxicity (DLT) rate and maximum tolerated dose (…

… survival or an acceptable biologic response. The reasons … antitumor benefit for advanced
non-small cell lung cancer (NSCLC… [64] showed that the combination of erlotinib with celecoxib …

… -of-opportunity trial to determine the biologic effects of … cyclooxygenase inhibitors, such as
celecoxib, for treatment of … We employed the nonlinear mixed effects model to determine the …

… that determine the feasibility of administering high-dose TKIs. In a … is the optimal biologic
dose reported for gefitinib [44,45,46,47]. To the best of our knowledge, this is the first study to …

… , excluding trials regarding breast, non-small cell lung cancer … 9 mg/m 2 of MTX as the optimal
biologic dose (OBD). In the … sirolimus in a Phase 1 trial in combination with celecoxib BID, …